Insider: Mehra Anand Director - Aclaris Therapeutics, Inc.
| Company Holdings |
| Direct | Indirect Ownership | Total | |
| Shares | 710,030 | 1,911,573 | 2,621,603 |
| Value | $1,412,959.70 | $3,804,030.27 | $5,216,989.97 |
Trans. Date |
Trans. Type |
Shares |
Ownership Type |
Issue Type |
Price |
Trans. Value |
Total Shares Owned |
|---|---|---|---|---|---|---|---|
| 11/19/2024 | AAP | 666,666 | Direct | COM | $2.25 | $1,499,998.50 | 710,030 |
| 10/22/2018 | AAP | 372,093 | Indirect | COM | $10.75 | $3,999,999.75 | 1,911,573 |
| 01/10/2017 | DDS | 750,000 | Indirect | COM | $28.25 | $21,188,325.00 | 1,539,480 |
| 10/13/2015 | AAP | 409,090 | Indirect | COM | $11.00 | $4,499,990.00 | 2,289,480 |
| 1 You are at page 1 of 1 pages |
|
Transaction Type Key First letter: A = Acquired, D = Disposed Second letter: A = Grant, award or other acquisition pursuant to Rule 16b-3(d) C = Conversion of derivative security | D = Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | E = Expiration of short derivative position | F = Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3. | G = Gift | H = Expiration (or cancellation) of long derivative position with value received | I = Discretionary transaction in accordance with Rule 16b-3(f) | J = Other | L = Small acquisition under Rule 16a-6 | M = Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | O = Exercise of out-of-the-money derivative security | P = Open market or private purchase | S = Open market or private sale | U = Disposition pursuant to a tender of shares in a change of control transaction | W = Acquisition or disposition by will or the laws of descent and distribution | X = Exercise of in-the-money or at-the-money derivative security | Z = Deposit into or withdrawal from voting trust |
 |
Send to Excel |
© 2000 - 2025 Zacks Investment Research